Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

139 results about "Transferrin receptor" patented technology

Transferrin receptor (TfR) is a carrier protein for transferrin. It is needed for the import of iron into the cell and is regulated in response to intracellular iron concentration. It imports iron by internalizing the transferrin-iron complex through receptor-mediated endocytosis. The existence of a receptor for transferrin iron uptake had been recognized over half a century back. Earlier two transferrin receptors in humans, transferrin receptor 1 and transferrin receptor 2 had been characterized and until recently cellular iron uptake was believed to occur chiefly via these two well documented transferrin receptors. Both these receptors are transmembrane glycoproteins. TfR1 is a high affinity ubiquitously expressed receptor while expression of TfR2 is restricted to certain cell types and is unaffected by intracellular iron concentrations. TfR2 binds to transferrin with a 25-30 fold lower affinity than TfR1. Although TfR1 mediated iron uptake is the major pathway for iron acquisition by most cells and especially developing erythrocytes, several studies have indicated that the uptake mechanism varies depending upon the cell type. It is also reported that Tf uptake exists independent of these TfRs although the mechanisms are not well characterized. The multifunctional glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH,EC 1.2.1.12) has been shown to utilize post translational modifications to exhibit higher order moonlighting behavior wherein it switches its function as a holo or apo transferrin receptor leading to either iron delivery or iron export respectively.

Diagnosis and treatment of cervical cancer

In certain aspects, the invention relates to methods of diagnosing cervical cancer by using a combination of certain biomarkers such as hTERT, IGFBP-3, transferrin receptor, beta-catenin, Myc-HPV E6 interaction, HPV E7, and telomere length. In other aspects, the invention relates to methods of detecting immortalization of cervical cells by using a combination of certain biomarkers. In yet other aspects, the invention relates to methods of classifying the grade of a cervical lesion for diagnostic and prognostic purposes in a female. In further aspects, the invention relates to methods of treating cervical cancer by administering a therapeutic agent that targets one or more of these biomarkers.
Owner:GEORGETOWN UNIV

Compositions for modulating blood-brain barrier transport

This invention provides conjugates of therapeutic or active agents with melanotransferrin or with other ligands of a melanotransferrin receptor, melanotransferrin receptor modulators, and related compositions and methods for modulating blood-brain barrier transport by providing methods of screening and selecting such conjugates, ligands, and modulators in vitro and in vivo, and methods of use of such conjugates, modulators and ligands in diagnosis and the treatment of diseases, including particularly diseases of the central nervous system or lysosomal storage diseases.
Owner:HORIZON ORPHAN LLC

Compositions and methods for modulating blood-brain barrier transport

This invention provides conjugates of therapeutic or active agents with melanotransferrin or with other ligands of a melanotransferrin receptor, melanotransferrin receptor modulators, and related compositions and methods for modulating blood-brain barrier transport by, providing methods of screening and selecting such conjugates, ligands, and modulators in vitro and in vivo, and methods of use of such conjugates, modulators and ligands in diagnosis and the treatment of diseases, including particularly diseases of the central nervous system or lysosomal storage diseases.
Owner:HORIZON ORPHAN LLC

Antihuman transferrin acceptor human source antibody and uses thereof

The invention relates to an anti-human transferrin receptor human antibody and the application, which pertains to the field of molecular biology. The anti-human transferrin receptor human antibody has a single-chain antibody (scFv) amino acid sequence which is shown in a sequence table SEQ ID No.1. The anti-human transferrin receptor human antibody and the application have the advantages that: the human antibody solves the problem of immunogenicity of the target antibody, thus allowing the human antibody to carry out the long-term repeated drug administrations in the human body; the method for screening a genetic engineering antibody in a large-capacity antibody library which is adopted by the invention is easier than the monoclonal antibody preparation, the large-scale production is easy, the molecule of the antibody is small, and the antibody can enter tissues deeply, thus having obvious advantages. A pET-22b (plus) vector which is adopted by the invention contains a stronger T7 promoter, which can ensure the higher expression level of the target antibody. The induced expression conditions after the optimization can ensure that the antibody is expressed in a soluble form and the activity of protein is higher. The 3' end of the pET-22b (plus) vector is provided with six His(histidine) labels, which can easily use the Ni-NTA agarose to carry out affinity chromatography and purification.
Owner:INST OF BIOENG ACAD OF MILITARY MEDICAL SCI OF THE CHINESE

Keratinocyte stem cells

Enrichment for human Keratinocyte Stem Cells KSCs to a high degree of purity can be successfully achieved on the basis of a cell surface component whose expression is proliferation-related in conjunction with an integrin such as the alpha6beta4 integrin. Transferrin receptor may be used as the cell surface component that is proliferation related. Enrichment of Transit amplifying cells can also be achieved by use of a variation of this method. The enrichment follows on from harvesting of cells from an epithelium, preferably rich in stem cells.
Owner:PETER MACCALLUM CANCER INST

Anti-growth factor receptor avidin fusion proteins as universal vectors for drug delivery

A fusion protein for delivery of a wide variety of agents to a cell via antibody-receptor-mediated endocytosis comprises a first segment and a second segment: the first segment comprising a variable region of an antibody that recognizes an antigen on the surface of a cell that after binding to the variable region of the antibody undergoes antibody-receptor-mediated endocytosis, and, optionally, further comprises at least one domain of a constant region of an antibody; and the second segment comprising a protein domain selected from the group consisting of avidin, an avidin mutein, a chemically modified avidin derivative, streptavidin, a streptavidin mutein, and a chemically modified streptavidin derivative. Typically, the antigen is a protein. Typically, the protein antigen on the surface of the cell is a receptor such as a transferrin receptor-or an insulin receptor. The invention also includes an antibody construct incorporating the fusion protein that is either a heavy chain or a light chain together with a complementary light chain or heavy chain to form an intact antibody molecule. The invention further includes targeting methods and screening methods.
Owner:RGT UNIV OF CALIFORNIA

Magnetic nano-grade material with cell-targeting property, and biomedical application thereof

The invention discloses a magnetic nano-grade material with a cell-targeting property, and a biomedical application thereof. The magnetic nano-grade material can be specifically bound with highly expressed transferrin receptors on tissue cell surfaces, and can enter the cells. The material can be bound with various high-transferring-receptor-expression tissue cells with broad spectrum and specificity, such that high-efficiency cell targeting property can be realized on animal models. The material can be used as a magnetic resonance contrast agent and a fluorescent molecular probe in disease diagnosis, and can be used as a medicine carrier in disease treatment.
Owner:INST OF GEOLOGY & GEOPHYSICS CHINESE ACAD OF SCI

Fusions of cytokines and tumor targeting proteins

A conjugate of a cytokine and a tumor targeting moiety (TTM) with the provisos that when cytokine is TNF-α, TNF-β or IFN-γ, the TTM is other than a CD13 ligant; when the cytokine is IL-12, the TTM is other than an antiboy to fibronectin; when the cytokine is TNF, the TTM is other than an antibody to the transferrin receptor, and when the cytokine is TNF, IFN-γ, or IL-2 the antibody is other than an antibody to the TAG72 antigen.
Owner:MOLMED SPA

Method of reducing expression of DUX4 in a muscle cell by administering an anti-transferrin receptor antibody linked to an oligonucleotide targeting DUX4

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
Owner:DYNE THERAPEUTICS INC

Diagnosis and treatment of cervical cancer

In certain aspects, the invention relates to methods of diagnosing cervical cancer by using a combination of certain biomarkers such as hTERT, IGFBP-3, transferrin receptor, beta-catenin, Myc-HPV E6 interaction, HPV E7, and telomere length. In other aspects, the invention relates to methods of detecting immortalization of cervical cells by using a combination of certain biomarkers. In yet other aspects, the invention relates to methods of classifying the grade of a cervical lesion for diagnostic and prognostic purposes in a female. In further aspects, the invention relates to methods of treating cervical cancer by administering a therapeutic agent that targets one or more of these biomarkers.
Owner:GEORGETOWN UNIV

DNA encoding a transferrin receptor of Moraxella

Purified and isolated nucleic acid molecules are provided which encode transferrin receptor proteins of Moraxella, such as M. catarrhalis or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce recombinant transferrin receptor proteins Tbp1 and Tbp2 of the strain of Moraxella free of other proteins of the Moraxella strain for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection.
Owner:CONNAUGHT LAB

Targeting nano diamond carrier and targeted drug, and preparation method and application thereof

The invention provides a targeting nano diamond carrier ND-PEG-Tf and a preparation method, and a targeted nano-drug ND-PEG-Tf-DOX prepared by loading chemotherapeutic adriamycin through physical absorption. The carrier interacts with a human liver cancer cell (HepG2) and a normal liver cell (L-02) and free transferrin is taken as a competitor, and the result indicates that the ND-PEG-Tf carrier is mediated by a transferrin receptor into the cells; MTT testing of interaction of ND-PEG-Tf-DOX with the two cells indicates that the nano-drug has targeted anti-tumor effect on cancer cells; and compared with the cell damage force of independent adriamycin, ND-PEG-Tf-DOX has the characteristics of a slow-release drug. Therefore, ND-PEG-Tf-DOX is capable of either reducing toxic and side effects of chemotherapeutics on normal cells or improving the damage force of the chemotherapeutics on tumor cells. In addition, the targeting nano diamond carrier can be applied to preparing targeted anti-tumor drugs.
Owner:SHANXI UNIV

Cancer specific promoters

The present invention regards cancer-specific control sequences that direct expression of a polynucleotide encoding a therapeutic gene product for treatment of the cancer. Specifically, the invention encompasses breast cancer-, prostate cancer-, and pancreatic cancer-specific control sequences. Two breast cancer-specific sequences utilize specific regions of topoisomerase IIα and transferrin receptor promoters, particularly in combination with an enhancer. The prostate cancer-specific and pancreatic cancer-specific control sequences utilize composites of tissue-specific control sequences, a two-step transcription amplification sequence, and a post-transcriptional control sequence. In more particular embodiments, these polynucleotides are administered in combination with liposomes.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Transferrin receptor transgenic models

In some aspects, the present invention provides chimeric transferrin receptor (TfR) polynucleotides and polypeptides. In other aspects, this invention provides chimeric TfR transgenic animal models and methods of using the animal models to identify therapeutics that can cross the blood-brain barrier.
Owner:DENALI THERAPEUTICS INC

Nucleic acid aptamer sequence for recognizing and being combined with human transferrin receptor and application of nucleic acid aptamer sequence

The invention discloses a nucleic acid aptamer sequence for recognizing and being combined with a human transferrin receptor and application of the nucleic acid aptamer sequence. A nucleic acid aptamer and derivatives thereof can be applied in kits, molecular probes and targeted media for recognizing or preparing and detecting transferrin receptor high-expression tumors and applied in nucleic acid probes for designing, preparing and detecting transferrin receptors. The nucleic acid aptamer has the advantages that the affinity and specificity are higher than those of the prior art, the aptamer is free of immunogenicity, chemical synthesis can be achieved, and the nucleic acid aptamer is small in molecular weight, stable, easy to store and mark and the like.
Owner:INST OF CHEM CHINESE ACAD OF SCI

Modified transferrin fusion proteins

InactiveCN101177456AReduce or prevent bindingSugar derivativesTransferrinsSerum igeTherapeutic protein
The present invention discloses modified fusion proteins of transferrin and therapeutic proteins or peptides, which have prolonged serum half-life or increased serum stability. Preferred fusion proteins include those modified such that the transferrin component exhibits no or reduced glycosylation, binding to iron, and / or binding to the transferrin receptor.
Owner:BIOREXIS PHARMA CORP

Novel Anti-Human Transferrin Receptor Antibody Capable of Penetrating Blood-Brain Barrier

Provided is an anti-human transferrin receptor antibody or an analog thereof, wherein in the heavy chain variable region of the antibody, (a) CDR1 comprises the amino acid sequence set forth as SEQ ID NO: 62 or SEQ ID NO: 63, (b) CDR2 comprises the amino acid sequence set forth as SEQ ID NO: 13 or SEQ ID NO: 14, and (c) CDR3 comprises the amino acid sequence set forth as SEQ ID NO: 15 or SEQ ID NO: 16, and an analogue thereof.
Owner:JCR PHARMA

Protein chip used for detecting human ferrum reserve and reagent kit thereof

InactiveCN102621330AImprove accuracyReduce harmBiological testingSoluble transferrin receptorNutrition
The invention discloses a protein chip used for detecting human ferrum reserve, which belongs to the field of human ferrum nutrition detection. The protein chip comprises a solid-phase carrier, antiserum ferritin monoclonal antibodies, antiserum transferrin receptor monoclonal antibodies and anti-C-reactive-protein monoclonal antibodies, wherein the antiserum ferritin monoclonal antibodies, the antiserum transferring receptor monoclonal antibodies and the anti-C-reactive-protein monoclonal antibodies are distributed on the solid-phase carrier in an array manner, wherein the monoclonal antibodies are fixed on the surface of the solid-phase carrier by covalent bonds, and the solid-phase carrier is finished by hydroformylation. The invention further discloses a detection reagent kit based on the protein chip. Compared with the prior art, the protein chip can detect three indexes of human ferrum reserve simultaneously, is accurate and reliable in results, high in detection specificity, sensitivity and detection speed and stable in detection results. Furthermore, by multi-sample microarray technology, the protein chip is applicable to screening and detecting of massive people, low in blood sample quantity, detection and cost and low in harms to examined people.
Owner:中国疾病预防控制中心营养与食品安全所

ph dependent antibodies targeting the transferrin receptor

A pH-dependent antibody that binds an antigen with high affinity at a first pH and rapidly dissociates at a second pH, wherein the antigen is a transferrin receptor (TfR), wherein the association at the second pH / the first pH is less than 20%, and wherein the pH-dependent antibody comprises at least two consecutive histidine residues at a single complementarity determining region (CDR) is disclosed.
Owner:WISCONSIN ALUMNI RES FOUND

Antihuman transferrin acceptor human source antibody and uses thereof

The invention relates to an anti-human transferrin receptor human antibody and the application, which pertains to the field of molecular biology. The anti-human transferrin receptor human antibody has a single-chain antibody (scFv) amino acid sequence which is shown in a sequence table SEQ ID No.1. The anti-human transferrin receptor human antibody and the application have the advantages that: the human antibody solves the problem of immunogenicity of the target antibody, thus allowing the human antibody to carry out the long-term repeated drug administrations in the human body; the method for screening a genetic engineering antibody in a large-capacity antibody library which is adopted by the invention is easier than the monoclonal antibody preparation, the large-scale production is easy, the molecule of the antibody is small, and the antibody can enter tissues deeply, thus having obvious advantages. A pET-22b (plus) vector which is adopted by the invention contains a stronger T7 promoter, which can ensure the higher expression level of the target antibody. The induced expression conditions after the optimization can ensure that the antibody is expressed in a soluble form and theactivity of protein is higher. The 3' end of the pET-22b (plus) vector is provided with six His(histidine) labels, which can easily use the Ni-NTA agarose to carry out affinity chromatography and purification.
Owner:INST OF BIOENG ACAD OF MILITARY MEDICAL SCI OF THE CHINESE

Drug delivery of temozolomide for systemic based treatment of cancer

The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and / or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and / or a polyethylene glycol (PEG) moiety.
Owner:CEDARS SINAI MEDICAL CENT

Docetaxel transferrin acceptor-targeted liposome preparation

The invention discloses a docetaxel transferrin acceptor-targeted liposome preparation. The preparation is prepared with a preparation method comprising the following steps of: mixing 55-95 parts by weight of phospholipid, 3-40 parts by weight of cholesterol and 0.05-20 parts by weight of docetaxel; dissolving into ethanol; performing rotary evaporation; adding 0.5-1.5ml of a phosphate buffer solution, and hydrating to obtain a liposome; and connecting a transferrin ligand to a liposome surface which contains docetaxel by applying a backward embedding technology to obtain a docetaxel transferrin acceptor-targeted liposome preparation, wherein the average particle diameter of the preparation is 60-100 nanometers, and the interfacial potential is -10mV to 20mV. As proved by a cytotoxicity research result, compared with a non-targeted liposome, a transferrin acceptor-targeted liposome has the advantage that: the toxicity of docetaxel on KB cells can be enhanced remarkably. The docetaxel transferrin acceptor-targeted liposome disclosed by the invention can become a novel medicament preparation for treatment cancers in future.
Owner:SHANDONG UNIV

Engineered receptor/ligand system for delivery of therapeutic agents

Provided herein are compositions and methods related to targeted delivery of a therapeutic or diagnostic agent to a subject utilizing an engineered receptor-ligand system, such as an engineered dockerin-cohesin system. As described herein, previously-developed targeted delivery systems for delivering therapeutic and diagnostic agents to a tissue of interest have drawbacks that have not been addressed to date. For example, with respect to the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB), both of which hamper delivery of agents to the brain, others have relied on the use of endogenously expressed receptors, like the transferrin receptor, to assist the agent across the barriers.
Owner:UNIV OF FLORIDA RES FOUNDATION INC

Polylysine oligomer modified recombined apoferritin nanometer cage and preparation thereof

The invention discloses a polylysine oligomer modified recombined apoferritin nanometer cage and a preparation thereof. The nanometer cage is a recombined apoferritin cage with the surface modified by polylysine oligomer that is acquired in the manner of self-assembling protein subunits into hollow spherical protein and utilizing a genetic recombination expression technique to modify different amount of lysine at the N terminal of the protein subunits. The protein nanometer cage can realize the depolymerization and recombination of the protein subunits by changing the solution pH so as to realize the drug loading; the biocompatibility and the in vivo stability are high; the nanometer cage can specifically recognize the high-expression transferrin receptor on the tumor cell surface, so as to realize the active targeting; after the recombined apoferritin nanometer cage is introduced into the cells under the endocytosis effect, the lysosome escape is realized through the proton sponge effect under the lysosome acid environment under the effect of polylysine residue, so that the drug in the protein cage can be protected from being degraded in the lysosome; the recombined apoferritin nanometer cage is expected to have an excellent application prospect at the aspects of gene drug delivery, drug organelle targeting delivery, and the like.
Owner:CHINA PHARM UNIV

Polypeptide drug exosome nano drug-loading system targeting cell membrane and preparation method of system

The invention provides a polypeptide drug exosome nano drug-loading system targeting a cell membrane and a preparation method of the system, and constructs the nano-delivery system (CTNF-alpha-exosome-SPION) having active targeting performance. Fusion polypeptides obtained through genetic engineering are distributed to the surfaces of exosomes, and SPION is connected to the exosomes through the combination of transferrin and transferrin receptors on the exosomes; with the help of an external magnetic field, the active targeting of the SPION allows a load drug to achieve a higher local concentration; and in addition, through lipophilicity of the fusion protein and delivery of the exosomes, more fusion protein is combined with receptors distributed on the cell surfaces to enhance activationactivity. The drug-loading system can deliver the polypeptide drug to the location of the polypeptide receptors on the cell surfaces of a lesion site, thereby improving the targeting and activation activity of the polypeptide drug.
Owner:饶磊

Novel brain targeting preparation for preventing and treating neurodegenerative disease

The invention provides a novel brain targeting preparation for preventing and treating a neurodegenerative disease. The novel brain targeting preparation comprises effective dose of fusion protein of cell growth factor and TAT (transcriptional activator) cell-penetrating peptide, or fusion protein of the cell growth factor, TAT and a transferrin receptor monoclonal antibody, a protein activity protecting agent, and proper auxiliary material, wherein the fusion protein of cell growth factor and TAT cell-penetrating peptide or the fusion protein of the cell growth factor, TAT and transferrin receptor monoclonal antibody is an active ingredient. The novel brain targeting preparation disclosed by the invention has excellent performance of breaking through a blood brain barrier, and is specifically targeted to the brain; the defect that single TAT does not have cell selectivity can be overcome; a brain neurons microenvironment is regulated and controlled by the effects of neurotrophy, paracrine and the like, so as to play the roles of preventing and treating the neurodegenerative disease. The novel brain targeting preparation can be prepared into a freeze-drying preparation, a liquid preparation or an adhesive preparation and applied in an intravenous injection or nasal delivery manner.
Owner:BIOPHARM RES & DEV CENT JINAN +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products